ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,949.33
0.16%
Gold vs US Dollar
2,305.475
-3.00%
Brent Oil
79.575
-0.38%
Bitcoin
71,133.69
0.52%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Incannex Healthcare Ltd (IXHL)

  7. Incannex Healthcare Ltd (IXHL) News

Incannex Healthcare (IXHL)

Incannex Healthcare Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IXHL
DateTimeSourceHeadlineSymbolCompany
30/05/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
30/05/202412:30GlobeNewswire Inc.Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
07/05/202412:30GlobeNewswire Inc.Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorderNASDAQ:IXHLIncannex Healthcare Ltd
16/04/202413:00GlobeNewswire Inc.Incannex Healthcare Inc. Quarterly Update, Q1 2024NASDAQ:IXHLIncannex Healthcare Ltd
28/02/202412:30GlobeNewswire Inc.Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety DisorderNASDAQ:IXHLIncannex Healthcare Ltd
16/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
16/02/202412:30GlobeNewswire Inc.Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking CessationNASDAQ:IXHLIncannex Healthcare Ltd
14/02/202411:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IXHLIncannex Healthcare Ltd
01/02/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
01/02/202412:30GlobeNewswire Inc.Clarion Clinics Open for Psychedelic-Assisted TreatmentsNASDAQ:IXHLIncannex Healthcare Ltd
24/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
24/01/202421:05GlobeNewswire Inc.Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid ArthritisNASDAQ:IXHLIncannex Healthcare Ltd
18/01/202414:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
18/01/202413:22GlobeNewswire Inc.Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis CommencesNASDAQ:IXHLIncannex Healthcare Ltd
17/01/202412:30GlobeNewswire Inc.Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
17/01/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
22/12/202311:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
22/12/202301:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
22/12/202301:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
22/12/202301:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
22/12/202301:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
21/12/202321:05GlobeNewswire Inc.Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in AustraliaNASDAQ:IXHLIncannex Healthcare Ltd
20/12/202322:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IXHLIncannex Healthcare Ltd
06/12/202312:30GlobeNewswire Inc.Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
29/11/202318:40GlobeNewswire Inc.Incannex Healthcare Announces Completion of its Redomiciliation to the United StatesNASDAQ:IXHLIncannex Healthcare Ltd
16/11/202314:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IXHLIncannex Healthcare Ltd
16/11/202313:30GlobeNewswire Inc.Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASICNASDAQ:IXHLIncannex Healthcare Ltd
08/11/202311:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IXHLIncannex Healthcare Ltd
26/10/202311:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IXHLIncannex Healthcare Ltd
08/09/202312:30GlobeNewswire Inc.Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023NASDAQ:IXHLIncannex Healthcare Ltd
 Showing the most relevant articles for your search:NASDAQ:IXHL

Your Recent History

LSE
PANR
Pantheon Resources
LSE
GDR
Genedrive
LSE
BP.
Bp
LSE
POS
Plexus
LSE
GGP
Greatland Gold
LSE
VAST
Vast Resources
LSE
LLOY
Lloyds Banking
LSE
EUA
Eurasia Mining
LSE
EEE
Empire Metals
LSE
SRT
Srt Marine Systems
LSE
PFC
Petrofac
LSE
TERN
Tern
LSE
I3E
I3 Energy
LSE
AAZ
Anglo Asian Mining
LSE
GKP
Gulf Keystone Petroleum
LSE
ZED
Zenova
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved